GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
2.980
-0.340 (-10.24%)
At close: Sep 4, 2026, 4:00 PM EDT
3.080
+0.100 (3.36%)
After-hours: Sep 4, 2026, 7:54 PM EDT
Company Description
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States.
The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
GlucoTrack, Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Erik Emerson |
Contact Details
Address: 301 Route 17 North, Suite 800 Rutherford, New Jersey 07070 United States | |
| Phone | 201 842 7715 |
| Website | glucotrack.com |
Stock Details
| Ticker Symbol | GCTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1506983 |
| CUSIP Number | 45824Q887 |
| ISIN Number | US45824Q8877 |
| Employer ID | 98-0668934 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | Chief Executive Officer and Director |
| Dr. Paul V. Goode Ph.D. | Chief Technical Officer, President and Director |
| Avner Gal MBA, MSc.EE | Co-Founder, Chairman Emeritus and Consultant |
| David Malka BA | Co-Founder |
| Vincent Wong | Chief Operations Officer |
| Dr. Mark Tapsak Ph.D. | Chief Scientific Officer |
| Drinda Benjamin | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 2, 2026 | SCHEDULE 13G | Filing |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 425 | Filing |
| Aug 28, 2026 | 8-K/A | [Amend] Current report |
| Aug 27, 2026 | 8-K | Current Report |
| Aug 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 10, 2026 | 8-K | Current Report |